CVRM

DE
EN
FR
IT

Our medicines
- Cardiovascular, Renal & Metabolism
  - Heart Failure
    - Forxiga® (Dapagliflozin)
  - Chronic Kidney Disease (CKD)
    - Forxiga® (Dapagliflozin)
  - Type 2 diabetes
    - Forxiga® (Dapagliflozin)
    - Xigduo® (Dapagliflozin/Metformin HCI)
  - Amyloidosis
    - Wainzua® (Eplontersen)
- Respiratory & Immunology
  - COPD
    - Trixeo® (Formoterol/Glycopyrronium/Budesonid)
  - Eosinophilic granulomatosis with polyangiitis (EGPA)
    - Fasenra® (Benralizumab)
  - Systemic lupus erythematosus (SLE)
    - Saphnelo® (Anifrolumab)
  - Asthma
- Oncology & Hematology
  - Breast Cancer
  - Hematology
    - Calquence® (Acalabrutinib)
  - Hepatocellular Carcinoma
    - Imfinzi® (Durvalumab) + Imjudo® (Tremelimumab)
  - Biliary Tract Cancer
    - Imfinzi® (Durvalumab)
  - Lung Cancer
  - Ovarian Cancer
    - Lynparza® (Olaparib)
  - Endometrial Cancer
    - Imfinzi® (Durvalumab)
  - Prostate Cancer
    - Lynparza® (Olaparib)
  - Muscle Invasive Bladder Cancer
    - Imfinzi® (Durvalumab)
  - Pancreatic Cancer
    - Lynparza® (Olaparib)
  - Gastric Cancer & Gastroesophageal adenocarcinoma (GC/GEJC)
    - Enhertu® (Trastuzumab Deruxtecan)
    - Imfinzi® (Durvalumab)
  - Tumor Agnostic
    - Enhertu® (Trastuzumab Deruxtecan)
- View all Medicines
Therapeutic Areas
- Cardiovascular, Renal & Metabolism
- Respiratory & Immunology
- Oncology
Contact us

Login

Enter Search Term

Home
Therapy areas
CVRM

This website is intended for healthcare professionals in Switzerland only.

Report side effects

Report quality complaint

Medical enquiries